A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The study is a Phase II, single center, randomized, open-label, placebo-controlled study in
male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis. All
subjects will receive BID topical applications of PAC-14028 cream or vehicle or Elidel cream
for up to 4 weeks.